NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE **TECHNOLOGY APPRAISAL PROGRAMME**

Equality impact assessment – Scoping

STA Sotagliflozin, in combination with insulin, for treating type 1 diabetes

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Approved by Associate Director (name):Melinda Goodall	
No.	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
Not relevant.	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
Not relevant.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
No.	
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of sotagliflozin, in

combination with insulin, for treating type 1 diabetes Issue date: November 2018 1 of 2

Date: ...20/11/2018.....

Technology Appraisals: Scoping
Equality impact assessment for the Single Technology Appraisal of sotagliflozin, in combination with insulin, for treating type 1 diabetes
Issue date: November 2018 2 of 2